Abstract 141P
Background
To investigate the correlation between different expression of CDK5RAP3 and UFM1 and the long-term survival of patients undergoing radical gastrectomy.
Methods
The expression of CDK5RAP3 and UFM1 in cancer and adjacent tissues of gastric cancer patients were detected, and their relationship with clinical pathological parameters and long-term prognosis were analyzed.
Results
Low expression of CDK5RAP3 was detected in 102 patients (78.5%), and UFM1 expression was low in 99 patients (76.2%), and the expression of the two was significantly positively correlated. Based on the co-expression of CDK5RAP3 and UFM1, we found that the low expression of CDK5RAP3 and UFM1 was closely related to the depth of invasion (P = 0.041), lymph node metastasis (p = 0.006), and TNM stage (P = 0.000). In Kaplan-Meier analysis, the prognosis of patients with low expression of CDK5RAP3 and UFM1 was significantly poorer than that of patients with high expression of CDK5RAP3 or UFM1 (p = 0.005), and could be used as an independent risk factor for the prognosis of the entire group of patients. The co-expression of CDK5RAP3 and UFM1 had the largest area under the ROC curve, and the patients’ long-term prognosis was better than the TNM stage alone, and has statistical significance (p <0.05).
Conclusions
The expressions of CDK5RAP3 and UFM1 are significantly reduced in gastric cancer tissues. The co-expression of CDK5RAP3 and UFM1 is an independent prognostic factor for gastric cancer. Combining the expression of the two can provide a more accurate prognostic model for predicting the overall survival of gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session